{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:02:28Z","timestamp":1765486948915,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","award":["2018QD009"],"award-info":[{"award-number":["2018QD009"]}],"id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["ZY2021013"],"award-info":[{"award-number":["ZY2021013"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clml.2023.08.017","type":"journal-article","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T09:35:43Z","timestamp":1693128943000},"page":"911-916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"given":"Rujiao","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongyun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2039-4233","authenticated-orcid":false,"given":"Songfu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.08.017_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.017_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.08.017_bib0003","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.08.017_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.017_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.08.017_bib0006","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.20961","article-title":"Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients","volume":"82","author":"Zangari","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.08.017_bib0007","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2011.01602.x","article-title":"Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients","volume":"86","author":"Zangari","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.08.017_bib0008","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/jir.2021.0057","article-title":"Prognostic significance of cytokine release syndrome in B cell hematological malignancies patients after chimeric antigen receptor T cell therapy","volume":"41","author":"Dong","year":"2021","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.clml.2023.08.017_bib0009","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.08.017_bib0010","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.21037\/atm-21-3376","article-title":"Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy","volume":"9","author":"Hu","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clml.2023.08.017_bib0011","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.2147\/CMAR.S174237","article-title":"Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2023.08.017_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3864948","article-title":"Acute leukemia induces senescence and impaired osteogenic differentiation in mesenchymal stem cells endowing leukemic cells with functional advantages","volume":"2019","author":"Bonilla","year":"2019","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.clml.2023.08.017_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-018-0407-7","article-title":"Mesenchymal stem cells show functional defect and decreased anti-cancer effect after exposure to chemotherapeutic drugs","volume":"25","author":"Somaiah","year":"2018","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.clml.2023.08.017_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-019-1081-7","article-title":"Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels","volume":"38","author":"Zhong","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.08.017_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jbo.2018.09.001","article-title":"Osteoblast suppression in multiple myeloma bone disease","volume":"13","author":"Adamik","year":"2018","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.clml.2023.08.017_bib0016","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","article-title":"Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?","volume":"32","author":"Xu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.08.017_bib0017","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/cells9040873","article-title":"IL7-IL12 engineered mesenchymal stem cells (MSCs) improve A CAR T cell attack against colorectal cancer cells","volume":"9","author":"Hombach","year":"2020","journal-title":"Cells"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:25Z","timestamp":1761871405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2152265023002781"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}